Supernus Pharmaceuticals, Inc. SUPN

Updated: 11 Aug 2026

NASDAQ | Biotech | Pharmaceuticals and central nervous system

No signal published yet

We already track Supernus Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Supernus Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Pharmaceuticals and central nervous system
We're already tracking Supernus Pharmaceuticals, Inc. — here are the latest events we've registered

Recent News

  • On August 3, 2026, Supernus announced a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock transaction to create a diversified central nervous system biopharmaceutical company. The combined entity is expected to generate approximately $2.2 billion in pro forma net revenue and operate under the Supernus name led by CEO Jack Khattar. The transaction is anticipated to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals.

What Firelda Watch includes for Supernus Pharmaceuticals, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Supernus Pharmaceuticals, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Bioarctic
BIOA B
BUY
Recipharm
RECI B
NEUTRAL
Viatris Inc.
VTRS
HOLD
Xbrane Biopharma AB (publ)
XBRANE
HOLD
AstraZeneca PLC
AZN
HOLD

Biotech

More companies in this sector

Want to follow Supernus Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Supernus Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Supernus Pharmaceuticals, Inc. SUPN
Supernus Pharmaceuticals — follow and we'll monitor it
Follow Supernus Pharmaceuticals free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.